Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma by Payne, Karl et al.
 
 
Circulating tumor DNA as a biomarker and liquid
biopsy in head and neck squamous cell carcinoma
Payne, Karl; Spruce, Rachel; Beggs, Andrew; Sharma, Neil; Kong, Anthony; Martin, Timothy;
Parmar, Satyesh; Praveen, Prav; Nankivell, Paul; Mehanna, Hesham
DOI:
10.1002/hed.25140
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Payne, K, Spruce, R, Beggs, A, Sharma, N, Kong, A, Martin, T, Parmar, S, Praveen, P, Nankivell, P & Mehanna,
H 2018, 'Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma',
Head & Neck. https://doi.org/10.1002/hed.25140
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Published in Head & Neck on 15/03/2018
DOI: 10.1002/hed.25140
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
BA S I C S C I E NCE REV I EW
Circulating tumor DNA as a biomarker and liquid biopsy in head
and neck squamous cell carcinoma
Karl Payne MRCS1 | Rachel Spruce PhD2 | Andrew Beggs PhD3 |
Neil Sharma PhD4 | Anthony Kong PhD5 | Timothy Martin FRCS1 |
Satyesh Parmar FRCS1 | Prav Praveen FRCS1 | Paul Nankivell PhD4 |
Hisham Mehanna PhD6
1Department of Oral and Maxillofacial Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
2Translational Laboratory Team, University of Birmingham, Birmingham, United Kingdom
3Department of Cancer and Genetics, University of Birmingham, Birmingham, United Kingdom
4Department of Head and Neck Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
5Department of Clinical Oncology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
6Institute of Head and Neck Studies and Education, Department of Head and Neck Surgery, University of Birmingham, Birmingham, United Kingdom
Correspondence
Karl Payne, Department of Oral and
Maxillofacial Surgery, Queen Elizabeth
Hospital Birmingham, Mindelsohn Way,
Birmingham, B15 2WB United
Kingdom.,
Email: karlpayne@doctors.org.uk
Section Editor: Patrick Ha, MD
Abstract
The use of circulating biochemical molecular markers in head and neck cancer holds
the promise of improved diagnostics, treatment planning, and posttreatment surveil-
lance. In this review, we provide an introduction for the head and neck surgeon of the
basic science, current evidence, and future applications of circulating tumor DNA
(ctDNA) as a biomarker and liquid biopsy to detect tumor genetic heterogeneity in
patients with head and neck squamous cell carcinoma (HNSCC).
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1 | INTRODUCTION
Head and neck cancer continues to carry a significant global
burden of disease.1,2 Of concern is the increasing incidence
and mortality of head and neck cancer, with a greater rise in
developing countries and a contrasting increase of oropha-
ryngeal cancer in developed countries.1,2 Although several
cancers have biomarkers that can diagnose disease and moni-
tor pretreatment and posttreatment tumor burden, for
example, prostate-specific antigen in prostate cancer or carci-
noma antigen (CA19-9) in pancreatic cancer, head and neck
cancer has no such test. Thus, head and neck cancer surveil-
lance relies on clinical and radiological findings.3 Patients
often present with advanced-stage disease and the features of
early invasion and metastasis create a significant morbidity
and impact upon quality of life.4 For these reasons, despite
advances in treatment, head and neck cancer 5-year survival
remains in the region of 60%, which is only slightly
improved over the past few decades.5
Using a blood test, circulating biochemical molecular
markers in head and neck cancer hold the promise of being
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able to improve diagnosis, planning, treatment monitoring,
and surveillance.6 A blood test carries little morbidity, can be
repeated at various time points during treatment, and is cost-
effective. One such suggested biomarker is the level of circu-
lating tumor DNA (ctDNA).7 The discovery that a proportion
of circulating DNA in patients with cancer may be tumor-
derived has created the potential for a so-called “liquid
biopsy,” as an alternative to a tissue biopsy, to characterize
tumor genetic features.8,9
This review provides an introduction to the biological
structure and function of circulating DNA. We discuss its use
as a biomarker of tumor burden, and the potential utilization
of ctDNA as a liquid biopsy in head and neck squamous cell
carcinoma (HNSCC) to identify tumor genetic heterogeneity.
We deliberately focus on HNSCC and a ctDNA-based liquid
biopsy. Although it is beyond the scope of this article, authors
should be aware of other circulating components that are
under investigation for use as a potential liquid biopsy in head
and neck cancer. For example, circulating tumor cells (CTCs)8
or circulating viral DNA, such as plasma human papillomavi-
rus DNA in oropharyngeal carcinoma10 and plasma Epstein-
Barr virus DNA in nasopharyngeal carcinoma.11
1.1 | Circulating tumor DNA
Circulating DNA is extracellular DNA found in circulating
blood, which was first identified as early as 1948.12 This
DNA is released into the circulation by both pathogenic and
physiological mechanisms, including apoptosis, cellular
necrosis, phagocytosis, or exocytosis.13 Ordinarily, circulat-
ing DNA is rapidly degraded by blood nucleases and elimi-
nated by the liver, spleen, and kidneys and has a short half-
life of around 10 to 15 minutes.13 Therefore, systemic illness,
such as liver or renal disease, can impact upon ctDNA levels
and potentially bias the interpretation of blood results.14
CtDNA is present in many forms; either free DNA, bound to
protein complexes, cell surface bound, or in vesicles (apopto-
tic bodies, microvesicles, and exosomes).13
In 1977, Leon et al15 were the first to identify that
patients with cancer had increased levels of circulating DNA
fragments, thus prompting the hypothesis that tumors
released DNA into the bloodstream. In 1989, Stroun et al16
were able to show that a portion of these DNA fragments
was in fact of tumor origin due to the presence of genome
instability, and then, in 1994, Sorenson et al17 demonstrated
the presence of tumor-specific point mutations in the KRAS
gene in ctDNA. The presence of cancer-specific genomic
alterations (for example, point mutations) allows the differen-
tiation between ctDNA and DNA from normal healthy
cells.9,13 An additional discriminating factor is the difference
in DNA fragment base pair length. Cellular apoptosis creates
DNA fragments of around 100 to 200 base pair, whereas
necrosis, due to more irregular digestion, creates larger frag-
ments sometimes many kilo-base pair in size.13,18
The concentration of circulating DNA in healthy control
patients is generally very low, in the region of <5 ng/mL,
whereas patients with cancer can have elevated levels of sev-
eral hundred ng/mL.13,18 The increase in ctDNA in patients
with cancer and the exact origin of ctDNA remains contro-
versial. As tumor size increases, outstripping the metabolic
supply, tissue hypoxia causes cellular necrosis, sloughing of
tumor cells, and, thus, release of ctDNA.13,18 The CTCs are
not discussed in this review but, in theory, lysis of these cells
in the circulation may also contribute to ctDNA, although
the evidence is mixed.10
It is not clear if ctDNA has an active role in carcinogenesis
or whether it is just a byproduct of tumor shedding. García-
Olmo et al19 were one of the first groups to describe the con-
cept that ctDNA could cause cancer metastases by transfecting
healthy cells. They were able to induce tumors in healthy rats
using plasma from tumor-bearing rats. The same group later
demonstrated that the serum from patients with colorectal can-
cer induced tumor formation in in vitro cultured cells.20
The laboratory methods of ctDNA detection and analysis
have changed greatly over the past few decades, with the
development of next-generation digital sequencing (NGS).
The predominant method for the analysis of ctDNA is via
polymerase chain reaction (PCR) amplification of ctDNA
gene targets followed by downstream analysis. A variety of
methods is used for the sensitive detection of point mutations,
including real-time PCR, digital droplet PCR, and Sanger-
type sequence. For more comprehensive molecular profiling
of the circulating tumor genome, whole genome amplification
methods (such as multiple displacement amplification, or ran-
dom hexamer amplification) can be used to amplify limited
ctDNA input followed by library preparation and sequenc-
ing.21 As can be seen, the protocol for the collection and anal-
ysis of a liquid biopsy assay is both complex and as yet not
standardized in its approach, with a major hurdle being the
sensitivity and error rate of NGS for ctDNA.14,21
1.2 | Clinical applications of circulating
tumor DNA
With numerous data end points described in ctDNA studies,
it is useful to clarify how each of these would impact upon
clinical practice. In previous literature, the terms “biomarker”
and “liquid biopsy” have at times been used interchangeably.
In this review, we deliberately separate the terms biomarker
and liquid biopsy as to avoid confusion. As opposed to a
static biopsy that determines tumor characteristics, a bio-
marker should be an objective and quantitative test of disease
progression and outcome.22 We discuss the clinical applica-
tion of ctDNA analysis in 2 broad categories: (1) a biomarker
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to assess tumor burden; and (2) a liquid biopsy to determine
tumor genetic heterogeneity (Table 1).
1.3 | Biomarker of tumor burden
To date, the use of ctDNA to assess HNSCC tumor burden
has focused on 2 areas: total ctDNA concentration and the
detection of ctDNA as a tool in diagnosis and marker of prog-
nosis. The use of a ctDNA liquid biopsy as a noninvasive
screening tool is an interesting proposition and is currently
under investigation. As with all screening tools, the technical
and clinical demands of creating a sensitive and specific
ctDNA-based test are immense. However, the development
of low-cost NGS technology and complex bioinformatics
data analysis make this concept a potential future reality.23
The immediate application of ctDNA as a biomarker in the
pretreatment phase will likely be for those patients in whom
there is high risk or diagnostic uncertainty. For example, the
monitoring of premalignant lesions in which the best course
of treatment is still debated or when a biopsy may miss poten-
tial malignancy in a severely dysplastic lesion.24 In the post-
treatment phase, the high sensitivity of ctDNA poses a real
opportunity for the first biomarker in HNSCC to assess for
residual disease or locoregional recurrence.
1.4 | Circulating tumor DNA levels and
detection in patients with cancer
As discussed, the finding that total circulating DNA con-
centration was increased in patients with cancer was the
foundation of the hypothesis that part of this DNA may
be of tumor origin. However, total ctDNA concentration,
regardless of subsequent ctDNA genomic analysis, may
also be used as a diagnostic and prognostic tool. Mazurek
et al25 assessed total circulating DNA levels in 200 patients
with HNSCC when compared to a control group of 15
patients. Mean total DNA levels were higher in the
HNSCC group but not up to significant levels. Of interest,
oropharyngeal SCCs had significantly higher levels of
ctDNA (P 5 .011) than other HNSCCs (nasopharynx,
hypopharynx, and larynx). They also demonstrated a signif-
icant relationship among nodal status (N0-1 vs N2-3), stage
(I-III vs IV), and age (<63 and >63) with increasing
ctDNA concentrations.
To be used as a biomarker, ctDNA detection must be a
sensitive test for HNSCC and correlate with severity of dis-
ease. In the largest study to date, Bettegowda et al26 evaluated
the detection of ctDNA in 359 patients with 15 various cancer
types. They divided the patients into those with localized dis-
ease (n 5 136) and those with metastatic disease (n 5 223),
unfortunately, the numbers of head and neck cancer cases
were relatively low (n 5 12). In the metastatic disease group,
ctDNA was detected in 82% of patients, in contrast to 55% in
the localized disease group. When evaluating ctDNA as a
prognostic tool, by comparing the metastatic and localized
groups in cancers with sufficient numbers (colorectal, gastro-
esophageal, pancreas, and breast), there was a significant rela-
tionship (P < .001) and also a clear trend with regard to
advancing stage of disease and increased ctDNA quantity.
1.5 | Posttreatment surveillance
The ability to use ctDNA as a biomarker of disease recur-
rence in the posttreatment surveillance phase is arguably
more valuable than its diagnostic merits.27 Given the reliance
on poorly sensitive clinical and radiographic tests, a bio-
marker of posttreatment tumor burden would be a valuable
tool.3 The study by van Ginkel et al27 discussed the role of
ctDNA in head and neck cancer surveillance, and proposed a
workflow for how this would be applied to clinical practice.
Studies in breast, colorectal, lung, and several other cancers
have all demonstrated the clinical application of ctDNA.8,9,13
In a study of 18 patients with colorectal cancer, Diehl et al28
were able to directly correlate ctDNA detection and fluctuat-
ing levels with recurrence-free survival postsurgical treat-
ment (P 5 .006). All but 1 of the patients who had
detectable ctDNA postoperatively experienced recurrence
and none of the patients with undetectable ctDNA experi-
enced recurrence. They were able to elegantly plot graphical
representations of ctDNA levels over time to provide an
accurate representation of “personal tumor dynamic burden.”
In a similar study, Dawson et al29 compared ctDNA to CTCs
and carcinoma antigen (CA15-3) in 30 patients with
TABLE 1 Clinical applications of circulating tumor DNA analysis
as a biomarker and liquid biopsy
Biomarker Liquid biopsy
Pretreatment
Diagnostic screening tool Tumor genotyping to deter-
mine driver mutations and
facilitate targeted molecu-
lar anticancer therapy
Diagnosis in uncertain cases
Rationale for treatment
protocol (ie, neck dissection in
node-negative neck)
Baseline evaluation of tumor
burden for posttreatment
comparison
Posttreatment
Assess residual disease in
immediate posttreatment
phase
Monitor clonal evolution and
assess for resistance driver
mutations in recurrent
cancerProvide risk analysis for
decision to give adjuvant
chemoradiotherapy
Surveillance for locoregional
recurrence
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metastatic breast cancer undergoing treatment. The ctDNA
was statistically more sensitive than CTCs or carcinoma anti-
gen (CA15-3) to measure treatment response (P < .002) and
was a significant marker of survival (P < .001).
In a study of 47 patients with HNSCC, Wang et al30
were able to collect postsurgical treatment samples from 9
patients. In 3 patients who developed recurrent disease, the
presence of ctDNA in plasma predated the clinical/radio-
graphic evidence of recurrence by 15 months, 9 months, and
<1 month. Of the 5 patients with negative ctDNA results, all
were recurrence free at a mean follow-up of 12 months.30
Hamana et al31 compared the detection of ctDNA in 64
patients with oral SCC in the preoperative and postoperative
phase. Forty-four percent of patients (28/64) demonstrated
ctDNA with tumor-specific microsatellite alterations preoper-
atively and this dropped to 20% (13/64) postoperatively. Of
the 28 preoperative patients with detectable ctDNA, 20 had
no ctDNA detectable postoperatively and all of these patients
were disease-free with no recurrence. Four of the patients
with detectable ctDNA at 4 weeks in the immediate postop-
erative phase went on to develop distant metastases. In this
study, the presence of cDNA was statistically correlated to
early-stage (I/II) versus late-stage (III/IV) disease (P 5
.0378).
1.6 | Liquid biopsy to assess tumor genetic
heterogeneity
The ability to identify driver mutations and epigenetic mod-
ifications of a tumor is an important step in the implemen-
tation of targeted therapy and improving outcomes in
patients with head and neck cancer. Because HNSCC
shows considerable tumor genetic heterogeneity, this means
that different parts of the tumor may have different muta-
tions.32 Knowledge of all the important “driver” mutations
of a tumor are necessary to be able to provide targeted
treatment for that tumor. The current use of tissue biopsy
as a diagnostic technique is a major deficiency in this
regard. A tissue biopsy captures 1 or 2 parts of a tumor,
and, therefore, is at high risk of bias and missing important
driver mutations due to intratumoral heterogeneity, together
with the invasiveness nature and morbidity of the procedure
itself.27 In contrast to the “static biopsy” obtained from tis-
sue samples, the ability to collect multiple liquid biopsies
at different time points during treatment creates the reality
of a “dynamic biopsy” to detect tumor clonal evolution and
identify recurrence or treatment resistance. This would
allow the potential for real-time monitoring of cancer
genetic mutational progression and the tailoring of person-
alized targeted molecular therapy. Recent studies in head
and neck cancer have focused on the identification of
tumor-specific genomic alterations in ctDNA. We discuss
each applicable genomic alteration in turn.
1.7 | Mutations
Lebofsky et al33 investigated tumor-specific mutations in the
ctDNA of 34 patients with 18 various types of metastatic
cancer (head and neck cancer 5 5). In 27 patients, ctDNA
mutations matched those from solid tumor biopsies. In the
aforementioned study of 47 patients with HNSCC by Wang
et al,30 they were able to detect plasma ctDNA with tumor-
specific point mutations in 87% of cases. They assessed the
presence of mutations in 6 genes (TP53, PIK3CA, CDKN2A,
FBXW7, HRAS, NRAS, and E7 [human papillomavirus]
DNA) frequently associated with HNSCC (>85% had TP53
mutations). The majority of patients had advanced (stage III
or IV) disease. When they combined findings from plasma
with sloughed DNA fragment detection in saliva this
increased the diagnostic sensitivity to 96%. Of note, there
was little variation in plasma detection rates among sites
(80% oral cavity, 91% oropharynx, 86% larynx, and 100%
hypopharynx). As expected, salivary DNA detection was sig-
nificantly higher in oral cavity tumors (100%) when com-
pared with other sites (47%-70%). Although mutation
frequency was higher with advanced-stage disease (70% vs
92%) this was not to statistical significance. They concluded
that the combination of DNA detection in 2 compartments
(plasma and saliva) was a valuable tool to increase
sensitivity.
1.8 | Microsatellite alterations
Microsatellite alterations include microsatellite instability
(MSI) and loss of heterozygosity (LOH). Microsatellites are
sections of DNA with short base pair motifs (usually 1-6
base pairs in length) repeated 5 to 100 times. In brief, they
signify a defective mismatch repair system, which in turn is
a marker of mutations in DNA repair genes.34 There is strong
evidence for the role of MSI in colorectal cancer as a marker
of prognosis and survival, but the role of MSI in head and
neck cancer is unclear.34 Some studies report no relationship,
whereas others reported a positive MSI conferring a better
prognosis. The LOH is a result of loss of a copy of a diploid
gene and is a common mechanism of inactivation of tumor
suppressor genes. In a recent review by De Schutter et al,34
they highlighted LOH as a more useful prognostic predictive
marker than MSI, due in part to an increased frequency of
LOH compared to MSI in HNSCC. The LOH is associated
with advanced high-grade disease and is a negative prognos-
tic indicator of survival,35 with suggested evidence of a cor-
relation with chemotherapy resistance.36
Some of the earliest work to identify HNSCC tumor-
specific genomic alterations in ctDNA was performed by
Nawroz et al.37 In a cohort of 21 patients, they identified
microsatellite alterations in the ctDNA of 6 patients with
HNSCC. All 6 patients had advanced (stage III-IV) disease
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and 5 had nodal metastases. The same group followed up
these preliminary findings with a larger study of 152 patients
with HNSCC.38 Forty-five percent of patients (68/152) had
tumor-specific microsatellite alterations in ctDNA, with 84%
of the cohort having advanced-stage or recurrent disease
(127/152). Those with advanced-stage disease and nodal
metastases had a higher positive rate of microsatellite altera-
tions than those with early-stage cancer. Of note, there was
an obvious jump in detection from stage I to II disease (17%
vs 47%) when compared to stage III and IV disease (52%
and 44%). With a mean follow-up period of 27 months,
disease-free survival was decreased in the positive ctDNA
detection group but not to statistical significance.
1.9 | Tumor suppressor gene
hypermethylation
The silencing of tumor suppressor genes via the hypermeth-
ylation of their promoter regions is one mechanism of gene
suppression involved in carcinogenesis.39 This epigenetic
phenomenon of hypermethylation has been investigated and
validated in HNSCC, with a host of tumor suppressor genes
implicated as potential targets.39 The detection of hypermeth-
ylation of ctDNA is, therefore, another potential prognostic
application in HNSCC.
Mydlarz et al40 evaluated the methylation status of 100
patients with HNSCC when compared to a control group of
50 patients. They specifically examined hypermethylation of
the EDNRB, DCC, and p16 (CDKN2A) genes. Ten patients
(10%) exhibited EDNRB hypermethylation, 2 of these
patients had DCC hypermethylation, and 1 of these 2 patients
also had p16 hypermethylation. It was statistically significant
that HNSCC samples had EDNRB amplification when com-
pared to the control group (P 5 .02) but not with the DCC
or p16 genes. It is difficult to ascertain the clinical utility of
this data. Detecting hypermethylated regions in ctDNA is
highly specific for a diagnosis of HNSCC but the sensitivity
is poor. Moreover, with tens of tumor suppressor genes
implicated in HNSCC,39 an assay with the diagnostic speci-
ficity to be used as a diagnostic screening tool would need to
evaluate each of these genes individually. One solution is to
perform genomewide analysis of DNA methylation, which is
a technique under investigation.41
1.10 | Future questions to answer about
circulating tumor DNA
For ctDNA to be used as a biomarker and liquid biopsy the
quantitation of ctDNA levels via the detection of genomic
alterations must be standardized and validated in HNSCC. A
gold standard investigation would need to take into account
patient, tumor, procedural, and treatment factors to produce a
risk-adjusted determination of prognosis and tumor
heterogeneity (Figure 1). Unfortunately, each of these factors
has unanswered research questions.
A significant challenge is the harmonization of the meth-
odology used to detect and analyze ctDNA.8,9 Herein lies the
problem of creating a validated and universally accepted bio-
marker/liquid biopsy assay with set parameters that can be
reproduced by different institutions. Furthermore, the muta-
tional ctDNA load seems to vary greatly between tumor type
and site,18,26,33 and stage of disease or therapy may not
always correlate with ctDNA levels.18 For example, Mazurek
et al25 noted that oropharyngeal SCC had significantly
greater levels of ctDNA than other HNSCC sites, the cause
for this is unknown but presumably individual tumor biology
has an impact. Thierry et al13 noted that tumor growth
kinetics and variance in cell proliferation and cell loss factors
will impact upon ctDNA levels. In addition, the impact of
systemic factors (comorbid disease, age, and smoking) on
the levels and clearance of circulating DNA is not fully
understood. The ability to quantify the above factors and
apply these calculations to individual patient samples
remains an unanswered task.
2 | CONCLUSION
As evidenced by this review, there are limited data relating
to HNSCC and ctDNA. The presence of ctDNA in HNSCC
seems to correlate with early versus late-stage disease and in
the postoperative phase may predict recurrence or metastasis.
The majority of studies provide proof-of-principle data that
lay the foundation for future clinical trials. This review
serves as an introduction for the head and neck surgeon into
this flourishing field of research and, in time, a systematic
review is required to further quantify all available data.
FIGURE 1 Factors influencing the application of circulating tumor
DNA as a biomarker and liquid biopsy. NGS, next-generation sequencing
[Color figure can be viewed at wileyonlinelibrary.com]
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Although other specialties have made great strides toward
the application of ctDNA analysis into clinical practice, pro-
gress has not been as rapid in head and neck oncology.
Despite this, the evidence is encouraging that ctDNA as a
biomarker and liquid biopsy holds great promise to provide a
noninvasive, cost-effective, and tumor-specific test in
HNSCC. The advent and further development of NGS tech-
nology is a turning point in this regard and the need for
robust clinical trials of ctDNA in HNSCC is paramount.
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